Iopofosine I-131 treatment in late-line patients with relapsed/refractory multiple myeloma post anti-BCMA immunotherapy

Detalles Bibliográficos
Autores principales: Longcor, Jarrod, Callander, Natalie, Oliver, Kate, Chanan-Khan, Asher, Ailawadhi, Sikander
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Correspondence
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9448804/
https://www.ncbi.nlm.nih.gov/pubmed/36068232
http://dx.doi.org/10.1038/s41408-022-00725-2
_version_ 1784784147475070976
author Longcor, Jarrod
Callander, Natalie
Oliver, Kate
Chanan-Khan, Asher
Ailawadhi, Sikander
author_facet Longcor, Jarrod
Callander, Natalie
Oliver, Kate
Chanan-Khan, Asher
Ailawadhi, Sikander
author_sort Longcor, Jarrod
collection PubMed
description
format Online
Article
Text
id pubmed-9448804
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-94488042022-09-08 Iopofosine I-131 treatment in late-line patients with relapsed/refractory multiple myeloma post anti-BCMA immunotherapy Longcor, Jarrod Callander, Natalie Oliver, Kate Chanan-Khan, Asher Ailawadhi, Sikander Blood Cancer J Correspondence Nature Publishing Group UK 2022-09-06 /pmc/articles/PMC9448804/ /pubmed/36068232 http://dx.doi.org/10.1038/s41408-022-00725-2 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Correspondence
Longcor, Jarrod
Callander, Natalie
Oliver, Kate
Chanan-Khan, Asher
Ailawadhi, Sikander
Iopofosine I-131 treatment in late-line patients with relapsed/refractory multiple myeloma post anti-BCMA immunotherapy
title Iopofosine I-131 treatment in late-line patients with relapsed/refractory multiple myeloma post anti-BCMA immunotherapy
title_full Iopofosine I-131 treatment in late-line patients with relapsed/refractory multiple myeloma post anti-BCMA immunotherapy
title_fullStr Iopofosine I-131 treatment in late-line patients with relapsed/refractory multiple myeloma post anti-BCMA immunotherapy
title_full_unstemmed Iopofosine I-131 treatment in late-line patients with relapsed/refractory multiple myeloma post anti-BCMA immunotherapy
title_short Iopofosine I-131 treatment in late-line patients with relapsed/refractory multiple myeloma post anti-BCMA immunotherapy
title_sort iopofosine i-131 treatment in late-line patients with relapsed/refractory multiple myeloma post anti-bcma immunotherapy
topic Correspondence
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9448804/
https://www.ncbi.nlm.nih.gov/pubmed/36068232
http://dx.doi.org/10.1038/s41408-022-00725-2
work_keys_str_mv AT longcorjarrod iopofosinei131treatmentinlatelinepatientswithrelapsedrefractorymultiplemyelomapostantibcmaimmunotherapy
AT callandernatalie iopofosinei131treatmentinlatelinepatientswithrelapsedrefractorymultiplemyelomapostantibcmaimmunotherapy
AT oliverkate iopofosinei131treatmentinlatelinepatientswithrelapsedrefractorymultiplemyelomapostantibcmaimmunotherapy
AT chanankhanasher iopofosinei131treatmentinlatelinepatientswithrelapsedrefractorymultiplemyelomapostantibcmaimmunotherapy
AT ailawadhisikander iopofosinei131treatmentinlatelinepatientswithrelapsedrefractorymultiplemyelomapostantibcmaimmunotherapy

Ejemplares similares